Closure of trading window for the quarter ended 31.12.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beryl Drugs Ltd has informed the stock exchange that its trading window for dealing in company securities will remain closed from 1 January 2026 until 48 hours after the declaration of unaudited financial results for the quarter ended 31 December 2025 (Q3 FY26). The closure applies to all board members, promoters, and designated/specified connected persons, in line with SEBI's Insider Trading Regulations, 2015. The date of the board meeting to approve the Q3 results will be communicated later. The notice was signed by Chairman & Director Sudhir Sethi.
This is a routine compliance filing and does not signal any positive or negative development. It simply restricts insiders from trading ahead of the upcoming Q3 results announcement, so it should have no direct impact on the stock price.